The presence of cartilage matrix glycoprotein in serum as determined by immunolocation analysis is not a sensitive indicator of "early" osteoarthritis of the knee

Rose Fife, Kenneth D. Brandt, Ethan M. Braunstein, Stephen L. Myers, Barry Katz, James Ehlich, K. Donald Shelbourne, Lorrie A. Kalasinski

Research output: Contribution to journalArticle

9 Citations (Scopus)

Abstract

Widespread effort is being devoted to the search for a serologic "marker" that could aid in the early diagnosis of osteoarthritis and in following the progression of the disease in response to treatment. It is obvious that such a marker would have its greatest utility in patients with mild or early osteoarthritis. CMGP is a disulfide-bonded 550,000 dalton cartilage matrix glycoprotein with a half-life of only 48 to 72 hours that has been found, through immunolocation analysis, in the serum of dogs with experimentally induced osteoarthritis and in the synovial fluid of patients with osteoarthritis but not other types of arthritis. To determine whether detection of CMGP in serum might be of value in identifying patients with "early" osteoarthritis, we examined serum samples from 26 patients with knee pain who had articular cartilage lesions of osteoarthritis at arthroscopy but whose knee radiographs were normal or showed only mild or moderate osteoarthritis. CMGP was identified by immunolocation analysis with specific antibodies. Eleven patients (42%) were seropositive for CMGP. In two, the degenerative cartilage lesions visualized at arthroscopy were mild (grade 2); in the other nine they were more severe (grade 3 or 4). However, 10 of the 15 seronegative patients also had grade 3 or 4 cartilage degeneration. Thus, this serum assay for CMGP was often negative in this group of patients in the presence of well-defined cartilage degeneration.

Original languageEnglish
Pages (from-to)332-338
Number of pages7
JournalJournal of Laboratory and Clinical Medicine
Volume117
Issue number4
StatePublished - 1991

Fingerprint

Matrilin Proteins
Knee Osteoarthritis
Cartilage
Osteoarthritis
Serum
Arthroscopy
Knee
Disulfides
Assays
Synovial Fluid
Articular Cartilage
Fluids
Antibodies
Arthritis
Half-Life
Disease Progression
Early Diagnosis
Dogs
Pain

ASJC Scopus subject areas

  • Medicine(all)
  • Pathology and Forensic Medicine

Cite this

The presence of cartilage matrix glycoprotein in serum as determined by immunolocation analysis is not a sensitive indicator of "early" osteoarthritis of the knee. / Fife, Rose; Brandt, Kenneth D.; Braunstein, Ethan M.; Myers, Stephen L.; Katz, Barry; Ehlich, James; Shelbourne, K. Donald; Kalasinski, Lorrie A.

In: Journal of Laboratory and Clinical Medicine, Vol. 117, No. 4, 1991, p. 332-338.

Research output: Contribution to journalArticle

Fife, Rose ; Brandt, Kenneth D. ; Braunstein, Ethan M. ; Myers, Stephen L. ; Katz, Barry ; Ehlich, James ; Shelbourne, K. Donald ; Kalasinski, Lorrie A. / The presence of cartilage matrix glycoprotein in serum as determined by immunolocation analysis is not a sensitive indicator of "early" osteoarthritis of the knee. In: Journal of Laboratory and Clinical Medicine. 1991 ; Vol. 117, No. 4. pp. 332-338.
@article{c338504fab554d31b5b6c5ee5b749b22,
title = "The presence of cartilage matrix glycoprotein in serum as determined by immunolocation analysis is not a sensitive indicator of {"}early{"} osteoarthritis of the knee",
abstract = "Widespread effort is being devoted to the search for a serologic {"}marker{"} that could aid in the early diagnosis of osteoarthritis and in following the progression of the disease in response to treatment. It is obvious that such a marker would have its greatest utility in patients with mild or early osteoarthritis. CMGP is a disulfide-bonded 550,000 dalton cartilage matrix glycoprotein with a half-life of only 48 to 72 hours that has been found, through immunolocation analysis, in the serum of dogs with experimentally induced osteoarthritis and in the synovial fluid of patients with osteoarthritis but not other types of arthritis. To determine whether detection of CMGP in serum might be of value in identifying patients with {"}early{"} osteoarthritis, we examined serum samples from 26 patients with knee pain who had articular cartilage lesions of osteoarthritis at arthroscopy but whose knee radiographs were normal or showed only mild or moderate osteoarthritis. CMGP was identified by immunolocation analysis with specific antibodies. Eleven patients (42{\%}) were seropositive for CMGP. In two, the degenerative cartilage lesions visualized at arthroscopy were mild (grade 2); in the other nine they were more severe (grade 3 or 4). However, 10 of the 15 seronegative patients also had grade 3 or 4 cartilage degeneration. Thus, this serum assay for CMGP was often negative in this group of patients in the presence of well-defined cartilage degeneration.",
author = "Rose Fife and Brandt, {Kenneth D.} and Braunstein, {Ethan M.} and Myers, {Stephen L.} and Barry Katz and James Ehlich and Shelbourne, {K. Donald} and Kalasinski, {Lorrie A.}",
year = "1991",
language = "English",
volume = "117",
pages = "332--338",
journal = "Translational Research",
issn = "1931-5244",
publisher = "Mosby Inc.",
number = "4",

}

TY - JOUR

T1 - The presence of cartilage matrix glycoprotein in serum as determined by immunolocation analysis is not a sensitive indicator of "early" osteoarthritis of the knee

AU - Fife, Rose

AU - Brandt, Kenneth D.

AU - Braunstein, Ethan M.

AU - Myers, Stephen L.

AU - Katz, Barry

AU - Ehlich, James

AU - Shelbourne, K. Donald

AU - Kalasinski, Lorrie A.

PY - 1991

Y1 - 1991

N2 - Widespread effort is being devoted to the search for a serologic "marker" that could aid in the early diagnosis of osteoarthritis and in following the progression of the disease in response to treatment. It is obvious that such a marker would have its greatest utility in patients with mild or early osteoarthritis. CMGP is a disulfide-bonded 550,000 dalton cartilage matrix glycoprotein with a half-life of only 48 to 72 hours that has been found, through immunolocation analysis, in the serum of dogs with experimentally induced osteoarthritis and in the synovial fluid of patients with osteoarthritis but not other types of arthritis. To determine whether detection of CMGP in serum might be of value in identifying patients with "early" osteoarthritis, we examined serum samples from 26 patients with knee pain who had articular cartilage lesions of osteoarthritis at arthroscopy but whose knee radiographs were normal or showed only mild or moderate osteoarthritis. CMGP was identified by immunolocation analysis with specific antibodies. Eleven patients (42%) were seropositive for CMGP. In two, the degenerative cartilage lesions visualized at arthroscopy were mild (grade 2); in the other nine they were more severe (grade 3 or 4). However, 10 of the 15 seronegative patients also had grade 3 or 4 cartilage degeneration. Thus, this serum assay for CMGP was often negative in this group of patients in the presence of well-defined cartilage degeneration.

AB - Widespread effort is being devoted to the search for a serologic "marker" that could aid in the early diagnosis of osteoarthritis and in following the progression of the disease in response to treatment. It is obvious that such a marker would have its greatest utility in patients with mild or early osteoarthritis. CMGP is a disulfide-bonded 550,000 dalton cartilage matrix glycoprotein with a half-life of only 48 to 72 hours that has been found, through immunolocation analysis, in the serum of dogs with experimentally induced osteoarthritis and in the synovial fluid of patients with osteoarthritis but not other types of arthritis. To determine whether detection of CMGP in serum might be of value in identifying patients with "early" osteoarthritis, we examined serum samples from 26 patients with knee pain who had articular cartilage lesions of osteoarthritis at arthroscopy but whose knee radiographs were normal or showed only mild or moderate osteoarthritis. CMGP was identified by immunolocation analysis with specific antibodies. Eleven patients (42%) were seropositive for CMGP. In two, the degenerative cartilage lesions visualized at arthroscopy were mild (grade 2); in the other nine they were more severe (grade 3 or 4). However, 10 of the 15 seronegative patients also had grade 3 or 4 cartilage degeneration. Thus, this serum assay for CMGP was often negative in this group of patients in the presence of well-defined cartilage degeneration.

UR - http://www.scopus.com/inward/record.url?scp=0025856306&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0025856306&partnerID=8YFLogxK

M3 - Article

VL - 117

SP - 332

EP - 338

JO - Translational Research

JF - Translational Research

SN - 1931-5244

IS - 4

ER -